Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$31.44 -0.88%

-$0.15 today

Market cap
$3.57B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 4.02M

Average 2.86M

Returns on capital

Viridian Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-47.4%

avg 279.3%

ROIC

-43.8%

avg -266.7%

ROA

-38.1%

avg -81.8%

Analysis

ROA is currently the strongest return metric at -38.1% versus its period average of -81.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Stephen F. Mahoney

Chief Executive Officer, President & DirectorUSD 1.34M5533.35K0.04%

Thomas W. Beetham

Chief Operating OfficerUSD 972.98K5613.36K0.01%

Radhika Tripuraneni

Chief Medical OfficerUSD 840.69K460<0.01%

Jennifer Tousignant

Chief Legal Officer & Corporate SecretaryUSD 819.95K530<0.01%

Seth Harmon

Chief Financial OfficerUSD 785.65K457.85K<0.01%

Melissa Manno

Chief Human Resources Officer————

Eric N. Olson

Co-Founder & Chairman of Scientific Advisory Board————

Marvin H. Caruthers

Co-Founder & Scientific Advisory Board Member—86——

Michael R. Bristow

Co-Founder & Member of the Scientific Advisory Board—81——

Vahe Bedian

Co-Founder & Scientific Advisor————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 19, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$20.00M

Sells

2

$315,795.52

Net Transaction Value

+$19.68M

Net buying

Most Active

Tousignant Jennifer

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 19, 26

Tousignant Jennifer

Direct

Sell$245K
May 11, 26

Fairmount Funds Management LLC

Indirect

Buy$20M
Dec 31, 25

Tousignant Jennifer

Direct

Sell$70.8K

Summary

Insiders reported 1 buys worth $20.00M and 2 sells worth $315,795.52 over the last 12 months. That adds up to net buying of $19.68M. Tousignant Jennifer was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+241.9%
+78.8% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +241.9% over three years. Forward estimates point to Revenue at +78.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Viridian Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about VRDN's management, answered from reported figures.

Who manages VRDN?

Viridian Therapeutics, Inc. (VRDN) lists 10 active executives. The top listed executive is Jennifer Tousignant, Chief Legal Officer & Corporate Secretary.

Are VRDN insiders buying or selling?

Recent insider activity shows net buying of $248.46M.